Phase 1/1b Study of RNDO-564 in Participants with Advanced Urothelial Cancer

2025-524687-38-00 Protocol RNDO-564-001 Human pharmacology (Phase I) - First administration to humans Authorised, recruitment pending

Status Authorised, recruitment pending · 1 EU/EEA countries · 6 sites · Protocol RNDO-564-001

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - First administration to humans
Status Authorised, recruitment pending
Participants planned 149
Countries 1
Sites 6

Other Solid Tumors Associated with Nectin-4 Expression

Key facts

Sponsor
Rondo Therapeutics Inc.
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Decision date (initial)
2026-06-17
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

External identifiers

EU CT number
2025-524687-38-00
ClinicalTrials.gov
NCT07218003

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Other Solid Tumors Associated with Nectin-4 Expression

VersionLevelCodeTermSystem organ class
27.0 LLT 10046730 Urothelial carcinoma urethra metastatic 10029104
28.0 SOC 10029104 Neoplasms benign malignant and unspecified (incl cysts and polyps) 2
27.0 LLT 10046728 Urothelial carcinoma urethra 10029104

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Rondo Therapeutics Inc.

Sponsor organisation
Rondo Therapeutics Inc.
Address
25801 Industrial Boulevard Suite 500
City
Hayward
Postcode
94545-2245
Country
United States

Scientific contact point

Organisation
Rondo Therapeutics Inc.
Contact name
Thomas Manley, MD

Public contact point

Organisation
Rondo Therapeutics Inc.
Contact name
Thomas Manley, MD

Locations

1 EU/EEA country · 6 investigational sites

By country

CountryMS statusPlanned subjectsSites
Spain Authorised, recruitment pending 34 6
Rest of world
United States, United Kingdom
115

Investigational sites

Spain

6 sites · Authorised, recruitment pending
Hospital Universitario Hm Sanchinarro
Centro Integral Oncológico Clara Campal (CIOCC); START Madrid, Calle Ona 10, 28050, Madrid
Hospital Clinico Universitario De Valencia
Oncología Medica, Avenida Blasco Ibanez 17, 46010, Valencia
Hospital Universitario Quironsalud Madrid
Oncología Médica; Next Oncology Madrid, Calle De Diego De Velazquez 1, 28223, Pozuelo De Alarcon
Hospital Clinic De Barcelona
Oncología Medica, Calle Villarroel 170, 08036, Barcelona
Hospital Universitari Vall D Hebron
Oncología Médica, Passeig De La Vall D'Hebron 119-129, 08035, Barcelona
Hospital Quironsalud Barcelona
Oncología Médica, Placa D'alfonso Comin 5-7, 08023, Barcelona

Application history

1 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2026-04-15 Spain Acceptable
2026-06-16
2026-06-17